Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells  by Dolma, Sonam et al.
A R T I C L E
Identification of genotype-selective antitumor agents using
synthetic lethal chemical screening in engineered human
tumor cells
Sonam Dolma,1 Stephen L. Lessnick,2,4 William C. Hahn,3,5 and Brent R. Stockwell1,*
1Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142
2 Department of Pediatric Oncology
3 Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115
4 Division of Hematology/Oncology, Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115
5 Departments of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115
*Correspondence: stockwell@wi.mit.edu
Summary
We used synthetic lethal high-throughput screening to interrogate 23,550 compounds for their ability to kill engineered
tumorigenic cells but not their isogenic normal cell counterparts. We identified known and novel compounds with genotype-
selective activity, including doxorubicin, daunorubicin, mitoxantrone, camptothecin, sangivamycin, echinomycin, bouvardin,
NSC146109, and a novel compound that we named erastin. These compounds have increased activity in the presence of
hTERT, the SV40 large and small T oncoproteins, the human papillomavirus type 16 (HPV) E6 and E7 oncoproteins, and
oncogenic HRAS. We found that overexpressing hTERT and either E7 or LT increased expression of topoisomerase 2
and that overexpressing RASV12 and ST both increased expression of topoisomerase 1 and sensitized cells to a nonapoptotic
cell death process initiated by erastin.
Introduction pounds might target oncoproteins directly or they might target
other critical proteins involved in oncoprotein-linked signaling
Molecularly targeted therapeutics represent a promising new networks. Compounds that have been reported to display syn-
approach to anticancer drug discovery (Shawver et al., 2002). thetic lethality include (1) the rapamycin analog CCI-779 in my-
Using this approach, small molecules are designed to inhibit eloma cells lacking PTEN (Shi et al., 2002), (2) Gleevec in BCR-
directly the very oncogenic proteins that are mutated or overex- ABL-transformed cells (Druker et al., 1996), and (3) a variety
pressed in specific tumor cell types. By targeting specific molec- of less well-characterized compounds (Stockwell et al., 1999;
ular defects found within tumor cells, this approach may ulti- Torrance et al., 2001).
mately yield therapies tailored to each tumor’s genetic makeup. Over the past several years, we and others have engineered
Two recent examples of successful molecularly targeted anti- a series of human tumor cells with defined genetic elements in
order to identify those critical pathways whose disruption leadscancer therapeutics are Gleevec (imatinib mesylate), an inhibitor
of the breakpoint cluster region-abelsen kinase (BCR-ABL) on- to a tumorigenic phenotype (Hahn et al., 1999, 2002; Lessnick et
al., 2002). We postulated that these experimentally transformedcoprotein found in Philadelphia chromosome-positive chronic
myelogenous leukemia (Capdeville et al., 2002), and Herceptin cells would permit us to identify genotype-selective agents from
both known and novel compound sources that exhibit synthetic(trastuzumab), a monoclonal antibody targeted against the
HER2/NEU oncoprotein found in metastatic breast cancers lethality in the presence of specific cancer-related alleles. Com-
pounds with genotype-selective lethality may serve as molecular(Mokbel and Hassanally, 2001).
A complementary strategy involves searching for genotype- probes of signaling networks present in tumor cells and might
serve as leads for subsequent development of clinically effectiveselective antitumor agents that become lethal to tumor cells
only in the presence of specific oncoproteins or in the absence drugs with a favorable therapeutic index.
The ability of genotype-selective compounds to serve asof specific tumor suppressors. Such genotype-selective com-
S I G N I F I C A N C E
Identifying genetic alterations that increase the sensitivity of human cells to specific compounds may ultimately allow for mechanistic
dissection of oncogenic signaling networks and tailoring chemotherapy to specific tumor types. We have developed a systematic
process for discovering small molecules with increased activity in cells harboring specific genetic changes. Using this system, we
discovered that several clinically used antitumor agents are more potent and more active in the presence of specific genetic
elements. Moreover, we identified a novel compound that selectively kills cells expressing the Small T oncoprotein and oncogenic
RAS. These genetically targeted small molecules may also serve as leads for development of anticancer drugs with a favorable
therapeutic index.
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and small T (ST) oncoproteins, and an oncogenic allele of HRAS
(RASV12). In a second series, cell lines were created in which
complementary DNA (cDNA) constructs encoding LT and ST
were used in place of the SV40 genomic construct that encodes
both of these viral proteins. In this latter series, ST was intro-
duced in the last stage, enabling us to test compounds in the
presence or absence of ST.
In a third series, we used cell lines derived from indepen-
dently prepared human TIP5 foreskin fibroblasts created by
introducing cDNA constructs encoding hTERT, LT, ST, and
RASV12 (Lessnick et al., 2002). In a fourth series, we used cell
lines derived from TIP5 fibroblasts created by introducing cDNA
constructs encoding hTERT, E6, E7, ST, and RASV12. In this
series, HPV E6 and E7, which inactivate p53 and RB, respec-
tively, serve a similar function as LT in the previous series.
However, by using HPV E6 and E7, we were able to observe
Figure 1. Experimentally transformed human cells the effects of inactivating, separately and independently, p53
BJ cells are primary human foreskin fibroblasts. BJ-TERT cells are derived from and RB. We report below the results of a large-scale screen for
BJ cells and express hTERT, the catalytic subunit of the enzyme telome- compounds that display selective killing of these engineered
rase. BJ-TERT/LT/ST cells are derived from BJ-TERT cells by introduction of a
tumorigenic cell lines.genomic construct encoding both simian virus 40 large (LT) and small T (ST)
oncoproteins. BJ-TERT/LT/ST/RASV12 tumor cells are derived from BJ-TERT/LT/
ST cells by introduction of an oncogenic allele of HRAS (RASV12) (Hahn et Results
al., 1999). BJ-TERT/LT/RASV12 cells are derived from BJ cells by introduction
of cDNA constructs encoding TERT, LT, RASV12, and a control vector (Hahn We attempted to identify compounds with increased potencyet al., 2002). BJ-TERT/LT/RASV12/ST cells are derived from BJ-TERT/LT/RASV12
or activity in the presence of hTERT, LT, ST, E6, E7, or RASV12.cells by introduction of a cDNA encoding ST (Hahn et al., 2002). TIP5 cells
Using engineered cell lines with these genetic elements, weare primary human foreskin fibroblasts. The TIP5-derived cell lines were pre-
pared by introducing vectors encoding hTERT, LT, ST, RAS, or the papillomavi- screened 23,550 compounds, comprising 20,000 compounds
rus E6 or E7 proteins, as shown. E6 and E7 can jointly substitute for LT (Lessnick from a combinatorial library, 1,990 compounds from the Na-
et al., 2002).
tional Cancer Institute diversity collection, and 1,540 biologically
active compounds that we had previously purchased and for-
matted into a screenable collection. In the primary screen, we
tested in quadruplicate the effect of treating tumorigenic BJ-molecular probes is based on the premise of chemical genet-
TERT/LT/ST/RASV12 engineered tumorigenic cells with eachics—that small molecules can be used to identify proteins and
compound for 48 hr at a concentration of 4 g/ml, correspond-pathways underlying biological effects (Schreiber, 1998; Stock-
ing to 10 M for a compound with a molecular weight of 400,well, 2000a, 2000b). For example, the observation that the natu-
which is the approximate median molecular weight of our librar-ral product rapamycin retards cell growth made possible the
ies. We measured cell viability using the dye calcein acetoxy-discovery of the mammalian Target of Rapamycin (mTOR) as
methyl ester (calcein AM) (Wang et al., 1993), which is a nonfluo-
a protein that regulates cell growth (Brown et al., 1994; Sabatini
rescent compound that freely diffuses into cells. In live cells,
et al., 1994). We have combined these two approaches, chemi-
calcein AM is cleaved by intracellular esterases, forming the
cal and molecular genetic, to discover pathways affected by anionic fluorescent derivative calcein, which cannot diffuse out
cancer-associated mutations. of live cells. Hence, live cells exhibit a green fluorescence when
Previous reports have indicated that it is possible to convert incubated with calcein AM, whereas dead cells do not. Com-
primary human cells into tumorigenic cells by the introduction pounds that displayed 50% or greater inhibition of staining with
of vectors expressing the hTERT and oncogenic RAS proteins the viability dye calcein AM in BJ-TERT/LT/ST/RASV12 cells were
as well as others that disrupt of the function of p53, RB, and subsequently tested in a 2-fold dilution series in BJ and BJ-
PP2A (Hahn et al., 1999, 2002; Hahn and Weinberg, 2002; Less- TERT/LT/ST/RASV12 cells to identify compounds that display
nick et al., 2002). We made use of a series of engineered human synthetic lethality, i.e., lethality in tumorigenic cells but not in
tumorigenic cells and their precursors, which were created by isogenic primary cells. We calculated the IC50 value (concentra-
introducing specific genetic elements into primary human fore- tion required to inhibit 50% of the calcein AM signal) for each
skin fibroblasts (Figure 1). A variety of characteristics of these compound in each cell line (Table 1) and thereby identified nine
engineered tumorigenic cells have been reported previously, compounds (Figure 2) that were at least 4-fold more potent in
including their doubling time, their resistance to replicative se- BJ-TERT/LT/ST/RASV12 tumorigenic cells relative to BJ primary
nescence and crisis in culture, their response to  irradiation, cells (i.e., compounds for which at least a 4-fold higher concen-
their ability to grow in an anchorage-independent fashion, and tration was required in BJ primary cells in order to obtain the
their ability to form tumors in immunodeficient mice (Hahn et same 50% inhibition of calcein AM signal). We report below a
al., 1999, 2002; Lessnick et al., 2002). more detailed analysis of these nine compounds.
In one series of engineered cells, the following genetic ele- Three of these compounds (doxorubicin, daunorubicin, and
ments were introduced sequentially into primary BJ fibroblasts: mitoxantrone) are in current clinical use as anticancer drugs,
the human catalytic subunit of the enzyme telomerase (hTERT), one (camptothecin) is a natural product analog of clinically used
anticancer drugs (topotecan and irinotecan), and one (echino-a genomic construct encoding the Simian Virus 40 large (LT)
286 CANCER CELL : MARCH 2003
A R T I C L E
Figure 2. Chemical structures of nine genotype-selective compounds
mycin) was recently tested in phase II clinical trials. All nine
compounds were subsequently tested in replicate at multiple
doses in each panel of engineered cells to confirm that the
observed selectivities were seen in multiple independently de-
rived cell lines (Figure 1 and Table 1).
We developed a selectivity metric that measures the shift
in the IC50 (concentration required for 50% inhibition of viability
signal) of a compound in two different cell lines. To calculate
this selectivity score between two cell lines, we divided the IC50
for a compound in one cell line by the IC50 for the same com-
pound in a second cell line. Thus, a compound that must be
used at a 4-fold higher concentration in one cell line relative to
a second cell line would have a selectivity score of 4. We calcu-
lated the “tumor selectivity score” for each compound by divid-
ing the IC50 value for the compound in the parental, primary BJ
cells by the IC50 value for the compound in engineered BJ-TERT/
LT/ST/RASV12 cells, containing all four genetic elements required
to create tumorigenic cells (Table 1).
These engineered tumorigenic cells make use of dominantly
acting viral oncoproteins such as LT, ST, E6, and E7. These viral
proteins are possibly involved in cell transformation in specific
forms of cancer, namely simian virus 40-induced malignant me-
sothelioma (Testa and Giordano, 2001) and human papillomavi-
rus-induced cervical carcinoma (Bosch et al., 2002), and have
been used to disrupt p53 and pRB function to transform cells
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in vitro and in vivo (Elenbaas et al., 2001; Jorcyk et al., 1998;
Perez-Stable et al., 1997; Rich et al., 2001; Sandmoller et al.,
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1995). We made use of these two different methods for inactivat-
ing cellular proteins (i.e., we tested the effects of both LT and
E6/E7-based inactivation of pRB and p53) in order to control
for idiosyncratic effects that might be observed with a specific
viral protein. We also confirmed the selectivity of these com-
pounds in a cell line expressing dominant-negative inhibitors of
p53 and pRB that are not derived from viral elements. This cell
line expresses (1) a truncated form of p53 (p53DD) that disrupts
tetramerization of endogenous p53, (2) a CDK4R24C mutant resis-
tant to inhibition by p16INK4A and p15INK4B (the major negative
regulators of CDK4), and (3) cyclin D1. We tested the effects
of the nine genotype-selective compounds at a range of concen-
trations in these cells, which we refer to as BJ-TERT/p53DD/
CDK4R24C/D1/ST/RASV12 cells (Table 1). We found that there was
an overall modest reduction in activity for all of the compounds
when tested in these cells, but that the overall results of our
analysis were unchanged by the use of nonviral proteins in this
cell line (Table 1).
We sought to determine the genetic basis of selectivity for
each compound. That is, for each compound, we attempted to
define the gene or combination of genes responsible for render-
ing cells sensitive to the compound (Table 1). We found that
these nine compounds could be categorized into three groups,
namely (1) compounds that displayed no simple genetic selec-
tivity, (2) compounds that displayed selectivity for cells harbor-
ing TERT and inactive RB, and (3) compounds that required the
presence of both oncogenic RAS and ST in order to exhibit
lethality.
The compounds in group 1, sangivamycin, bouvardin,
NSC146109, and echinomycin, have no clear genetic basis for
their tumorigenic cell selectivity. For example, echinomycin be-
comes somewhat more active as each genetic element is intro-
duced (Figure 3A). As we have observed that the rate of cell
proliferation increases when each of these genetic elements is
introduced, it is likely that the compounds in group 1 are simply
selective for rapidly dividing cells. Supporting this interpretation
is the fact that all of these compounds are reported to act by
inhibiting DNA or protein synthesis, the need for which is greater
in rapidly dividing cells. For example, echinomycin is reported
to function as a DNA bis-intercalator (Van Dyke and Dervan,
1984; Waring and Wakelin, 1974), bouvardin is reported to func-
tion as a protein synthesis inhibitor (Zalacain et al., 1982), sangi-
vamycin is a nucleotide analog (Rao, 1968), and NSC146109
structurally resembles a DNA intercalator (Figure 2). It should
be noted that sangivamycin has been reported to function as
a PKC inhibitor (Loomis and Bell, 1988), although this activity
seems unlikely to be relevant in this context because other
PKC inhibitors displayed no selectivity in this system (data not
shown). We were able to identify and discard compounds that
are simply more active in rapidly dividing cells, such as these Figure 3. Effect of echinomycin and camptothecin on engineered cells
group 1 compounds, because they show no clear genetic basis The indicated cells were treated with echinomycin (A) or camptothecin (B
of selectivity. Thus, we were able to focus our mechanistic and C) in 384-well plates for 48 hr. Percent inhibition of cell viability, mea-
sured using calcein AM, is shown. Error bars indicate one standard deviation.studies on the more interesting compounds in groups 2 and 3.
A: Echinomycin-treated BJ, BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12The compounds in group 2, mitoxantrone, doxorubicin, and
cells.daunorubicin, are topoisomerase II poisons, which bind to topo- B: Camptothecin-treated BJ, BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12
isomerase II and DNA and prevent the religation of double- cells.
C: Camptothecin-treated BJ-TERT/LT/RASV12, BJ-TERT/LT/RASV12/ST and BJ-strand DNA breaks introduced by topoisomerase II. These com-
TERT/LT/ST/RASV12 cells.pounds, and anthracyclines in general, have also been reported
to induce the formation of reactive oxygen species (ROS) in
some cell types (Laurent and Jaffrezou, 2001; Muller et al., 1998;
Richard et al., 2002), although we did not observe the formation
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of ROS in these engineered cells in the presence of these three
compounds (data not shown). We discovered that these com-
pounds become more potent (i.e., active at a lower concentra-
tion) when hTERT is introduced and again when RB is inacti-
vated by introduction of LT or HPV E7. In our cells, E7 was
introduced after E6, so it is possible that the increased potency
of these compounds in cells harboring E7 also relies on the
presence of E6, even though E6 by itself does not confer in-
creased potency to these compounds. We determined that in-
troduction of hTERT and inactivation of RB caused an increase
in topoisomerase II expression (Figure 5A) and only a very
modest increase in topoisomerase II expression (data not
shown). Introduction of oncogenic RAS causes a further in-
crease in topoisomerase II expression, although we did not
observe a further sensitization to the topoisomerase II poisons
in the presence of oncogenic RAS (Figure 5A).
The compounds in group 3 are camptothecin (CPT) and a
novel compound from a combinatorial library, which we have
named erastin, for eradicator of RAS and ST-expressing cells
(Figure 2). Efficient CPT-induced and erastin-induced cell death
requires the presence of both ST and RASV12 (Figures 3 and 4
and Table 1). Although CPT and erastin have a similar genetic
basis of selectivity, they have distinct mechanisms of action.
CPT is partially active in cells lacking RB function (via expression
of E7), whereas erastin is not, and CPT requires 2 days to cause
death in BJ-TERT/LT/ST/RASV12 cells, while erastin is 100%
effective within 18 hr (data not shown and Figures 3 and 4). The
phosphatase inhibitor okadaic acid was capable of sensitizing
otherwise resistant BJ primary cells to CPT (Figure 5E), possibly
because okadaic acid upregulates TOP1 (Figure 5F). Okadaic
acid does not render BJ or BJ-TERT cells sensitive to erastin
(data not shown), consistent with a model in which CPT and
erastin act via distinct mechanisms. Moreover, we found that
the lethal compound podophyllotoxin, a tubulin inhibitor, does
not sensitize BJ or BJ-TERT cells to CPT, confirming that the
sensitization of BJ cells to CPT by okadaic acid is specific (data
not shown) and not the result of two weak cell death stimuli
having an additive, but functionally irrelevant, effect.
In attempting to understand the molecular basis for the
increased sensitivity to CPT of RASV12- and ST-expressing cells,
we determined the expression level in our engineered cells of
topoisomerase I (TOP1), the putative target of CPT (Andoh et
al., 1987; Bjornsti et al., 1989; Champoux, 2000; D’Arpa et al.,
1990; Eng et al., 1988; Hsiang et al., 1989; Hsiang and Liu,
1988; Liu et al., 2000; Madden and Champoux, 1992; Tsao et
al., 1993). We discovered that cells expressing both RASV12 and
ST upregulate TOP1 (Figure 5B). As CPT’s putative mechanism
of action in other cell types involves a gain of function, namely
introduction of double-strand DNA breaks in a TOP1-dependent
Figure 4. Effect of erastin on engineered cellsmanner (Liu et al., 2000), upregulation of TOP1 could explain
The indicated cells were treated with erastin in 384-well plates for 48 hr.the increased sensitivity of RASV12- and ST-expressing cells to
Percent inhibition of cell viability, measured using calcein AM, is shown.
CPT. In support of this interpretation, we found that genetic Error bars indicate one standard deviation.
inactivation of TOP1 with a small interfering RNA (siRNA) in A: Erastin-treated BJ, BJ-TERT, BJ-TERT/LT/ST, and BJ-TERT/LT/ST/RASV12 cells.
B: Erastin-treated BJ-TERT/LT/RASV12 cells (lacking ST), BJ-TERT/LT/RASV12/ST (tu-BJ-TERT/LT/ST/RASV12 cells confers partial resistance to CPT
morigenic cells), and BJ-TERT/LT/ST/RASV12 (tumorigenic cells).(Figures 5C and 5D).
C: Independently derived TIP5/TERT, TIP5/TERT/E6, TIP5/TERT/LT, TIP5/TERT/LT/We sought to characterize the type of cell death induced ST, and TIP5/TERT/LT/ST/RASV12 cells.
by CPT and erastin in tumorigenic BJ-TERT/LT/ST/RASV12 cells
(Figure 6). In other contexts, CPT has been found to induce
apoptotic cell death (Traganos et al., 1996), which is character-
ized by alterations in nuclear morphology including pyknosis,
karyorhexis, and/or margination of chromatin (Majno and Joris,
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Figure 5. Protein targets of tumor-selective compounds are upregulated in engineered tumorigenic cells
A–C: Western blot of lysates from BJ, BJ-TERT, BJ-TERT/LT/ST, BJ-TERT/LT/ST/RASV12, BJ-TERT/LT/RASV12, and BJ-TERT/LT/RASV12/ST cells with an antibody directed
against topoisomerase II (A) or TOPI (B and C). In (C), cells were transfected with an siRNA directed against TOPI, lamic A/C, or with a control double-
strand DNA duplex of the same length (TOPI dsDNA). In each case, the blot was probed with an antibody against eIF-4E to identify differences in the
amount of protein loaded. The relative amount is quantitated below each band.
D: A TOPI siRNA prevents cell death caused by camptothecin in engineered tumor cells. Cell number was determined after transfection with an siRNA
directed against TOPI and treatment with the indicated concentrations of camptothecin.
E: Okadaic acid, an inhibitor of PP2A and other cellular phosphatases, sensitizes primary human cells to camptothecin. BJ primary cells were treated
simultaneously with the indicated concentrations of both camptothecin and okadaic acid, and the effect on calcein AM viability staining was determined.
Although okadaic acid kills BJ cells at the highest concentrations tested, at 3.4 nM it has no effect on its own, but it renders BJ cells sensitive to camptothecin.
F: Okadaic acid stimulates expression of TOP1. BJ primary cells were treated with the indicated concentrations of okadaic acid, and the expression level
of TOPI was determined by Western blot. The relative amount is quantitated below each band.
1995). To determine whether erastin or CPT induces apoptosis Further supporting this conclusion were our observations that
CPT, but not erastin, induces DNA fragmentation (i.e., formationin our system, we monitored the nuclear morphology of CPT-
and erastin-treated tumorigenic cells using fluorescence mi- of a DNA ladder), that a pan-caspase inhibitor (50 M Boc-
Asp(Ome)-fluoromethyl ketone, Sigma #B2682 [Chan et al.,croscopy. Although karyorhexis and margination of chromatin
were clearly visible in CPT-treated cells, no such morphological 2001]) partially blocked cell death induced by CPT, but not by
erastin (data not shown), and that CPT, but not erastin, causedalternation was visible in erastin-treated cells (Figure 7A). Since
nuclear morphological change is required of apoptotic cells, we an increase in Annexin V staining (Figure 7B) and the appearance
of cleaved, active caspase 3 (Figure 7C).conclude that cell death induced by erastin is nonapoptotic.
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Figure 6. Erastin induces rapid cell death in a ST/
RASV12-dependent fashion
A: Time-dependent effect of erastin on BJ-TERT
and BJ-TERT/LT/ST/RASV12 cells. Cells were seeded
in 384-well plates in the presence of the indi-
cated concentrations of erastin. Inhibition of cell
viability was determined after 24, 48, and 72 hr
using calcein AM.
B: Effect of erastin on Alamar Blue viability stain-
ing in BJ-TERT (red) and BJ-TERT/LT/ST/RASV12
(blue) cells.
C: Photograph of BJ-TERT/LT/ST/RASV12 and BJ pri-
mary cells treated with erastin. Cells were al-
lowed to attach overnight, then treated with 9
M erastin for 24 hr and photographed.
Erastin’s ability to induce nonapoptotic cell death is selective genetic elements. Although previous reports indicated that it
for ST- and RASV12-expressing cells. Longer treatments and may be possible to identify such genotype-selective com-
higher concentrations of erastin had little effect on the viability pounds in the case of one genetic element of interest (Simons
of cells lacking RASV12 and ST, confirming the qualitative nature et al., 2001; Stockwell et al., 1999; Torrance et al., 2001), our
of erastin’s selectivity (Figures 6A and 6C). As erastin-treated efforts here provide a systematic testing of synthetic lethality
cells do not undergo apoptosis, we sought to confirm that eras- using more than 23,000 compounds and six cancer-related ge-
tin genuinely induces cell death, rather than cell detachment. netic elements.
We quantitated cell viability in the presence of erastin using The nine selective compounds we identified help to define
Alamar Blue (Ahmed et al., 1994), a viability dye that measures consequences of introducing TERT, LT, ST, E6, E7, and onco-
intracellular reductive potential. We found that erastin exhibited genic RAS into normal human cells. One effect of these genetic
selective lethality in tumorigenic BJ-TERT/LT/ST/RASV12 cells changes is to increase the rate of cell proliferation and to allow
relative to BJ-TERT cells in this homogeneous Alamar Blue sensitivity to small molecules that inhibit DNA synthesis. Al-
viability assay (Figure 6B). BJ-TERT/LT/ST/RASV12 cells treated though it is well established that such agents preferentially target
with erastin for 18 hr rounded up and detached (Figure 6C), rapidly replicating tumor cells, it is reassuring to see this princi-
failed to exclude the vital dye Trypan Blue, displayed a loss of ple emerge from this unbiased screening approach. Moreover,
mitochondrial membrane potential as assayed by the potentio-
we are able to readily discard these less interesting compoundsmetric dye JC-1, and had a small cell size characteristic of dead
because they lack a clear genetic basis of selectivity.cells (data not shown). We determined that the loss of viability
Second, we discovered that expression of hTERT and eitherinduced by erastin is irreversible once completed, in that BJ-
E7 or LT sensitizes cells to topoisomerase II poisons. Since lossTERT/LT/ST/RASV12 cells treated with erastin for 24 hr rounded
or inactivation of RB (Sellers and Kaelin, 1997; Sherr, 2001) andup, detached, and were unable to recover when replated in
activation of telomerase (Hahn and Weinberg, 2002; Harley,erastin-free medium. Thus, erastin induces rapid (12–24 hr),
1994) are found in most human cancers, these observationsirreversible, nonapoptotic cell death in a ST- and RASV12-depen-
may explain, in part, the activity of these agents in a diversedent fashion.
range of human tumor types.
Third, we discovered that camptothecin is selectively lethalDiscussion
to cells harboring both ST and oncogenic RAS because of the
combined effect of these two genes on expression of topoisom-We have demonstrated that it is possible to identify compounds
with increased potency and activity in the presence of specific erase I. Rapidly dividing tumor cells use topoisomerase I to
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Figure 7. Camptothecin, but not erastin, induces characteristics of apoptosis
A: Camptothecin-treated, but not erastin-treated, BJ-TERT/LT/ST/RASV12 cells displayed fragmented nuclei (10%–20% of total nuclei, red and blue arrows)
as shown.
B: Camptothecin-treated, but not erastin-treated, BJ-TERT/LT/ST/RASV12 cells display Annexin V staining. The percentage of cells in the indicated M1 region
were 6%, 6%, and 38% in untreated, erastin-treated (9 M), and camptothecin-treated (1 M), respectively.
C: Camptothecin-treated, but not erastin-treated, BJ-TERT/LT/ST/RASV12 cells harbor activated caspase 3. Lysates of camptothecin- and erastin-treated
samples were analyzed by Western blot with an antibody directed against the active, cleaved form of caspase 3. The blot was reprobed with an antibody
directed against eIF4E to control for loading levels.
unwind supercoiled DNA to effect continuous and rapid cell in which both of these pathways are perturbed show increased
susceptibility to these compounds.division. When these two pathways are simultaneously altered,
Finally, we have identified a novel compound, which wetopoisomerase I is upregulated, perhaps indirectly, and such
named erastin, that is only lethal to cells expressing both STtumor cells are rendered sensitive to topoisomerase I poisons.
and RASV12. Treatment of cells with this compound failed to killThese observations suggest that one aspect of the ability
cells lacking RASV12 and ST, even when used at concentrationsof ST to transform human cells along with RASV12, LT, and hTERT
8-fold higher than was required to observe an effect on cellsmay be the effect of ST and RASV12 on expression of topoisomer-
expressing both RASV12 and ST, indicating a degree of specific-ase I. Mutations in HRAS and KRAS have been described in
ity. The lethal effect of erastin is rapid and irreversible oncemany types of human cancers. Moreover, the inactivation of
obtained.
PPP2R1B, a component of PP2A, has recently been reported For both CPT and erastin, we identified synergy between
in colon and lung tumors (Wang et al., 1998), while mutations pathways altered by expression of RASV12 and ST. Expression
in a different PP2A subunit have been described in melanoma, of RASV12 leads to the activation of several well-characterized
lung, breast, and colon cancers (Calin et al., 2000; Kohno et signaling pathways, including the RAF-MEK-MAPK signaling
al., 1999; Ruediger et al., 2001a, 2001b). At present, it remains cascade, the phosphatidylinositol 3-kinase (PI3K) signaling
unclear whether simultaneous alteration of these two pathways pathway, and the Ral-guanine dissociation factor pathway (Ral-
GDS). Each of these pathways have been implicated in humanoccurs at high frequency in human tumors or whether cancers
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Aldrich Co. Bouvardin (MW 772.84) and NSC146109 (MW 280.39) werecancers, and recent work demonstrates that these pathways
obtained from the National Cancer Institute’s Developmental Therapeu-work in concert in this system of cell transformation (Hamad et
tics Program. Erastin (MW 545.07) was obtained from Comgenex Interna-al., 2002). In addition, ST binds to and inactivates PP2A, a widely
tional, Inc.
expressed serine-threonine phosphatase. Although the specific
enzymatic targets of PP2A that are perturbed upon expression Calcein AM viability assay
of ST are not yet known, there is substantial overlap among Calcein acetoxylmethyl ester (AM) is a cell membrane-permeable, nonfluo-
rescent compound that is cleaved by intracellular esterases to form thepathways altered by PP2A and RAS (Millward et al., 1999).
anionic, cell-impermeable, fluorescent compound calcein. Viable cells areUnderstanding further the mechanism by which erastin induces
stained by calcein because of the presence of intracellular esterases anddeath in cells harboring alterations of these two signaling path-
because the intact plasma membrane prevents fluorescent calcein fromways may provide clues to the nature and extent of functional
leaking out of cells (Wang et al., 1993). Cells were seeded in 384-well plates
overlap between these two pathways. using a Zymark Sciclone ALH, treated with each compound in triplicate at
Finally, these studies have provided a link between ST and 4 g/ml in the primary screen for 2 days, washed with phosphate-buffered
saline on a Packard Minitrak with a 384-well washer, and incubated for 4RASV12 signaling and a rapid and selective, nonapoptotic cell
hr with 0.7 g/ml calcein (Molecular Probes). Total fluorescence intensity indeath pathway operative in human fibroblasts. Identifying novel
each well was recorded on a Packard Fusion platereader and converted tomechanisms for killing tumor cells, particularly in a genotype-
a percent inhibition of signal by subtracting the instrument background andselective fashion, would be of value for understanding tumor
dividing by the average signal obtained when cells were not treated with
cell biology and development of new classes of antitumor any compound.
agents. Some have argued that most existing antitumor agents
kill tumor cells via apoptosis (Makin, 2002), highlighting the Alamar Blue viability assay
Alamar Blue is reduced by mitochondrial enzyme activity in viable cells,potential importance of our finding that erastin acts through a
causing both colorimetric and fluorescent changes (Nociari et al., 1998).novel, nonapoptotic pathway. The discovery of these signaling
Cells were seeded at a density of 6000 cells (50 l) per well in a 384-interactions was made possible by our combined use of chemi-
well black, clear-bottom plate using a syringe bulk dispensor (Zymark). Tencal genetic and molecular genetic approaches to tumor cell
microliters were removed from a 2-fold serially diluted erastin plate (6 final
biology. Although we have made use of hTERT, LT, ST, E6, E7, concentration) using a 384 fixed cannula head, making the final concentration
and RASV12 as transforming genes, future studies can make 20 g/ml in the well with highest concentration. The plates were incubated
use of a wide variety of cancer-associated alleles using this for 24 hr. Alamar Blue (Biosource International) was added to each well by
diluting 1:10 and incubated for 16 hr at 37C. Fluorescence intensity wasmethodology in order to define the signaling networks that ema-
determined using a Packard Fusion platereader with an excitation filter cen-nate from many oncogenes and tumor suppressors. Such stud-
tered on 535 nm and an emission filter centered on 590 nm. Average percent-ies may ultimately unravel details of these and other critical
age inhibition at each concentration was calculated. Error bars indicate onesignaling networks altered by oncogenic mutations.
standard deviation. The Alamar Blue assay does not involve washing the
cells.
Experimental procedures
ScreeningConstructs and retroviruses
Replica daughter plates were prepared with a Zymark Sciclone ALH andExpression constructs for hTERT, LT, ST, SV40 Early Region, and HRASV12
integrated Twister II by diluting stock plates 50-fold in medium lacking serumwere used as previously described (Hahn et al., 1999, 2002). hTERT-pWZL-
and pen/strep to obtain a compound concentration in daughter plates of 80Blast, E6-pWZL-zeo, and E6E7-pWZL-Zeo were previously described
g/ml with 2% DMSO. Assay plates were prepared by seeding cells in black,(Lessnick et al., 2002). The E6 and LT cDNAs were cloned into the pWZL-
clear bottom 384-well plates in columns 1–23 (6000 cells/well in 57 l) usingHygro retroviral vector (a kind gift from J. Morgenstern, Millenium Pharma-
a syringe bulk dispenser. Columns 3–22 were treated with compounds fromceuticals). Vesicular stomatitis virus-G glycoprotein pseudotyped retrovi-
a daughter library plate by transferring 3 l from the daughter library plateruses were prepared, and infections carried out as described previously
using 384-position fixed cannula array. The final compound concentrations(Lessnick et al., 2002).
in assay plates were thus 4 g/ml. The assay plates were incubated for 48
hr at 37C in humidified incubator containing 5% CO2. Plate processing forCell lines
the calcein AM viability assay was performed using an integrated Minitrak/TIP5 primary fibroblasts (Lessnick et al., 2002) were prepared from discarded
Sidetrak robotic system from Packard Bioscience (Perkin Elmer). Assayneonatal foreskins and were immortalized by infection with hTERT-pWZL-
plates were washed with phosphate-buffered saline, and 20 l of calceinblast or hTERT-pBabe-hygro retroviruses and selection with either blastici-
AM (0.7 g/ml) per well was added. Plates were incubated at room tempera-din or hygromycin, respectively. BJ cells were a gift of Jim Smith. hTERT-
ture for 4 hr. Fluorescence intensity was determined using a Fusionimmortalized fibroblasts were infected with the indicated retroviruses and
platereader with filters centered on an excitation of 485 nm and an emissionselected for the appropriate markers. All BJ derivatives were cultured in a
of 535 nm.1:1 mixture of DMEM and M199 supplemented with 15% inactivated fetal
bovine serum, penicillin, and streptomycin (pen/strep). TIP5 cells were grown
Retesting of compounds in a dilution seriesin DMEM containing 10% FBS and pen/strep. All cell cultures were incubated
Compounds to be retested were purchased from manufacturers. Stocksat 37C in a humidified incubator containing 5% CO2.
were prepared in DMSO at a concentration of 1 mg/ml in 384-well polypropyl-
ene plates with a 16-point, 2-fold dilution dose curve of each compound inCompound libraries
a column, in duplicates. Columns 1, 2, 23, and 24 were left empty for controls.An annotated compound library (ACL) comprising 1540 compounds, an NCI
Daughter retest plates were prepared from stock retest plate by dilutingdiversity set of 1990 compounds obtained from the National Cancer Institute,
66.6-fold in DMEM in 384-well deep-deep well plates (4.5 l transfer intoand a combinatorial library (Comgenex International, Inc.) containing 20,000
300 l). Cells were seeded at a density of 6000 per well in 40 l, and 20 lcompounds were used in the tumor-selective synthetic lethal screens. All
was added from a daughter retest plate. The plates were incubated for 2compound libraries were prepared as 4 mg/ml solutions in DMSO in 384-
days at 37C with 5% CO2.well polypropylene plates (columns 3–22) and stored at 	20C. Campto-
thecin (cat# C9911, MW 348.4), doxorubicin (cat# D1515 MW 580.0), dauno-
Data analysisrubicin (cat# D8809, MW 564.0), mitoxantrone (cat# M6545, MW 517.4),
Mean RFU (relative fluorescence units) for untreated cells was calculatedokadaic acid (cat# O4511, MW 805.0), echinomycin (cat# E4392, MW 1101),
and sangivamycin (cat# S5895, MW 309.3) were obtained from Sigma- by averaging columns 1, 2, and 23 (wells with cells but lacking compounds).
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The calcein background was calculated by averaging column 24 (wells with 1:1000 dilution). The protein loading level was determined by stripping and
calcein, but lacking cells). Percentage inhibition of each well was calculated reprobing the same blot with an antibody directed against eIF-4E (BD Biosci-
as (1	 [RFU	 calcein control]/[untreated cell	 calcein control]·100). Com- ences, Cat# 610270, 1:500 dilution). Alternatively, 1 106 cells were seeded
pounds causing at least 50% inhibition of calcein staining in the primary in 60 mm dishes and grown overnight at 37C with 5% CO2, then lysed with
screen were tested for selectivity toward BJ-TERT/LT/ST/RASV12 engineered 150 l of lysis buffer. Cells were removed with a scraper and transferred to
tumor cells by testing in BJ primary and BJ-TERT/LT/ST/RASV12 cells at a microcentrifuge tubes and incubated on ice for 30 min. The protein contents
range of concentrations. Selective compounds were retested in all engi- in the lysates were quantified using a Biorad protein estimation assay re-
neered cell lines. agent. Equal amounts of protein were loaded on 10% gradient SDS-poly-
acrylamide gel. The electrophoresed proteins were transblotted onto PVDF
Nuclear morphology assay membrane. After blocking with 5% dry milk, the membrane was incubated
200,000 tumorigenic BJ-TERT/LT/ST/RASV12 cells were seeded in 2 ml on with mouse anti-Human topoisomerase I antibody (Pharmingen) overnight
glass coverslips in each well of a 6-well dish, treated with nothing (NT), 9 at 4C, then with anti-mouse peroxidase conjugate antibody (Santa Cruz
M erastin, or 1.1 M camptothecin (CPT) in growth medium for 18 hr while Biotechnology).
incubating at 37C with 5% CO2. Nuclei were stained with 25 g/ml Hoechst
33342 (Molecular Probes) and viewed using an oil immersion 100 objective Annexin V-FITC Apoptosis Assay
on a fluorescence microscope. BJ-TERT/LT/ST/RASV12 cells were seeded at 1  106 cells per dish in 100
mm dishes and allowed to grow overnight. Cells were treated with erastin
Cell size measurements (5 or 10 g/ml) for 6, 8, or 11 hr. A camptothecin-treated (0.4 g/ml) control
200,000 BJ-TERT/LT/ST/RASV12 cells were seeded in 6-well dishes in 2 ml was maintained, treated at the time of seeding for 20 hr. After the treatment,
growth medium only (No treatment), with 9 M erastin, or with 1.1 M cells were harvested with trypsin/EDTA and washed once with fresh medium
camptothecin (CPT). After 24 hr, cells were released with trypsin/EDTA and containing serum and then twice with phosphate-buffered saline. Cells were
diluted to 10 ml in growth medium, and the cell size distribution of each resuspended in 1 binding buffer (BD Pharmingen) at a concentration of
sample was determined on a Coulter Counter. 1  106 cells/ml. 100 l (1  105 cells) was incubated with 5 l of Annexin
V-FITC (BD Pharmingen) and propidium iodiode (BD Pharmingen) for 15 min
Cell counting assay for camptothecin activity in the dark at room temperature. Then 400 l of the 1 binding buffer was
BJ-TERT/LT/ST/RASV12 cells were seeded in 6-well dishes (200,000 cells/ added and the cells analyzed by flow cytometry (Becton-Dickinson). Data
well; 2 ml per well) and transfected in serum- and antibiotic-free medium were acquired and analyzed using Cellquest software. Only viable cells that
using Oligofectamine (Life Technologies), with 100 nM siRNA per well in a did not stain with propidium iodiode were analzyed for Annexin V-FITC
total volume of 1 ml. 500 l of medium containing 30% FBS was added 4 staining using the FL1 channel.
hr after transfection. Cells were treated with the indicated concentrations
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